Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard first-line therapy for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR-sensitizing mutations [1]. Here, EGFR is linked to non-small cell lung carcinoma.